GENEVA – A giant World Health Organization study suggests that the antiviral drug remdesivir has not helped hospitalized patients COVID-19, unlike an earlier study that made the drug of interest in the United States and many other countries.
The effects announced on Friday do not contradict past effects and the WHO review was not as rigorous as the previous one conducted through the US National Institutes of Health. But they are based on considerations about the price of the expensive drug, as none of the studies have done so. proven to be able to survive.
The drug is not approved for COVID-19 in the United States, but authorized for emergency use after the previous test found that it reduced recovery time by an average of five days. It is approved for use as opposed to COVID-19 in the UK and Europe. , and it’s one of the remedies that U. S. President Donald Trump won when he got angry this month.
The WHO review involved more than 11,000 patients in 30 countries. Approximately 2,750 were randomly assigned to download re-ivir. The rest gained hydroxychloroquine, an antimalarial drug, immune formula booster interferon, combined lopinavir-ritonavir antiviral, or simply the same usual treatment. Other drugs have been largely excluded for COVID-19 through previous studies, but not re-dependency.
Mortality rates after 28 days, the need for breathing apparatus and hospital internment time were similar for patients receiving remdesivir compared to the same previous care.
The effects were not published in a journal or reviewed by independent scientists; however, they were published in a device that researchers use to temporarily percent the effects.
“The great story is the discovery that remdesivir has no significant effect on survival,” Martin Landray, a professor at The University of Oxford, said in a statement that he has conducted additional studies on the treatment of coronavirus.
“It’s a drug that wants to be given by intravenous infusion for five to 10 days” and its price is around $2,550 depending on the treatment, he said. “COVID affects millions of people and their families around the world. We want scalable and equitable treatments. “
WHO spokeswoman Dr. Margaret Harris attributed the difference in the findings of the two studies to the fact that the WHO is larger.
“It’s a much harder study,” he said. This is 4 times the number of other people in all other studies. “
However, Dr. Andre Kalil, an infectious disease specialist at the University of Nebraska who helped lead the reinfection test in the US. The U. S. , he said the WHO review was poorly designed, making his findings less reliable. Patients and doctors knew what remedy they were using, there was no placebo infusion to avoid sesa liver reports of dangers or benefits, there was little data on the severity of patients’ symptoms at the start of the remedy and many missing data, he said.
“The design of a poor quality test can be corrected by a giant pattern size, regardless of its size,” Kalil wrote in an email.
In addition, the WHO study tested 10 days of remdesivir, so some patients may have been hospitalized longer than full treatment, making their duration poor compared to others receiving the same care as usual.
Remdesivir’s author, Gilead Sciences, said in a statement that the findings are inconsistent with more rigorous studies and have not been fully reviewed or published.
———
Marchione back from Milwaukee.
———
The Associated Press Department of Health and Science is supported by the Department of Scientific Education at Howard Hughes Medical Institute. The AP is for all content only.
———
This story has been corrected to an erroneous reference to the reused malaria drug.
24/7 policy of the latest news and events